Compare RANI & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | STIM |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 88.4M |
| IPO Year | 2021 | 2018 |
| Metric | RANI | STIM |
|---|---|---|
| Price | $0.68 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.50 | $3.00 |
| AVG Volume (30 Days) | 634.8K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.14 | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | $1,633,000.00 | ★ $52,776,000.00 |
| Revenue This Year | $274.77 | $11.10 |
| Revenue Next Year | $79.44 | $11.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | N/A |
| 52 Week Low | $0.39 | $0.80 |
| 52 Week High | $3.87 | $4.84 |
| Indicator | RANI | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 70.44 |
| Support Level | $0.45 | $1.21 |
| Resistance Level | $0.83 | $2.13 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 20.70 | 89.31 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.